Healthcare of Ontario Pension Plan Trust Fund Has $13.17 Million Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Healthcare of Ontario Pension Plan Trust Fund lifted its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 13.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 658,900 shares of the biotechnology company's stock after purchasing an additional 80,400 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund owned 0.28% of ADMA Biologics worth $13,171,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Hollencrest Capital Management acquired a new position in ADMA Biologics during the third quarter valued at approximately $30,000. Larson Financial Group LLC bought a new position in shares of ADMA Biologics in the 3rd quarter valued at $31,000. Quest Partners LLC acquired a new position in shares of ADMA Biologics during the 2nd quarter worth $29,000. Harvest Fund Management Co. Ltd bought a new stake in shares of ADMA Biologics during the 3rd quarter worth $62,000. Finally, USA Financial Formulas boosted its stake in ADMA Biologics by 8.6% in the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock valued at $136,000 after buying an additional 539 shares in the last quarter. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Trading Down 7.9 %

Shares of ADMA stock traded down $1.72 during mid-day trading on Friday, reaching $20.11. 4,002,265 shares of the stock traded hands, compared to its average volume of 3,622,850. The company has a market cap of $4.75 billion, a price-to-earnings ratio of 72.86 and a beta of 0.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The stock's fifty day simple moving average is $19.08 and its two-hundred day simple moving average is $15.23. ADMA Biologics, Inc. has a 1-year low of $3.60 and a 1-year high of $23.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. During the same period last year, the company earned $0.01 EPS. On average, research analysts anticipate that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ADMA has been the subject of a number of research reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. Raymond James upped their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research report on Friday, November 8th. Finally, HC Wainwright raised their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, November 8th.

Insider Buying and Selling

In related news, Director Lawrence P. Guiheen sold 9,000 shares of the company's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. This represents a 5.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Brad L. Tade sold 15,000 shares of the firm's stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares of the company's stock, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their position. The disclosure for this sale can be found here. 3.70% of the stock is currently owned by insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.